

DENIPLANT

Deniplant BioTech

The next generation of asymmetric Multi-JAK/TYK2 inhibitors, delivered through botanical nanomedicine.



Synthetic JAK inhibitors hit the entire immune system



Non-selective blockade

Current synthetic treatments indiscriminately inhibit multiple JAK pathways, not just the hyperactive ones.



Severe side effects

Impaired hematopoiesis (JAK2/JAK3), severe hepatotoxicity, and risk of long-term biochemical dependency.



Access barrier

Synthetic biologic therapies remain extremely expensive and hard to access on a global scale.

THE SOLUTION

Asymmetric inhibitors delivered via plant exosomes



The Innovation

A portfolio of asymmetric Multi-JAK/TYK2 inhibitors delivered via plant-derived exosomes — 100% natural nanoparticles.




Unique Selectivity

Precise targeting of hyperactive JAK1 and TYK2 inflammatory pathways, while vital immunity stays intact.



Clinical Benefit

Maximum therapeutic efficacy, zero systemic toxicity, and easy oral administration.



JAK1 / TYK2

selective targeting via plant exosome

Convergence of structural AI + Cryo-EM + bio-orthogonal click chemistry



Structural AI

AlphaFold 3 for structural prediction of JAK/TYK2 targets.



Cryo-EM

Cryogenic electron imaging for atomic-resolution validation of compounds.



Click Chemistry

Bio-orthogonal chemistry for precise coupling of bioactive compounds onto the TYK2 domain.



Microfluidics

Controlled microfluidic self-assembly — eco-friendly production, costs cut by up to 90%.

In silico screening for atomic-level mapping of bioactive compounds on the TYK2 pseudokinase domain.

30 years of clinical results. IP protected worldwide.

30 years

OSIM

PCT



of preliminary clinical results,
thousands of patients improved
through the parent brand
Deniplant

active invention patent for the
original Deniplant formula
(psoriasis tea)

international patent in preparation
for the new nanotech product

Future IP strategy: the new nanotech product will be protected by an International Patent (PCT), securing intellectual property worldwide.

Two revenue engines, one technology platform

01

B2B IP Licensing

Licensing formulas and nanoparticle encapsulation technology to global pharma corporations.


02

Direct-to-Market (B2C Premium)

Distribution of premium, cGMP-standardized nutraceuticals directly to medical networks and patients.

MARKET OPPORTUNITY

A market exceeding \$150 billion, seeking non-toxic alternatives



TAM — GLOBAL MARKET

over \$150 billion

Global market for autoimmune disease treatments.

SAM — TARGET SEGMENT

JAK inhibitors

Market for JAK inhibitors and targeted biologic therapies.

SOM — SERVICEABLE MARKET

EU + US

Patients seeking non-toxic alternatives in the EU and US.

Founders with 30 years of combined expertise



Gheorghe Giurgiu

Co-founder & CEO

30 years pioneering phytotherapy, holder of the Deniplant OSIM patent.



Prof. Dr. Manole Cojocaru

Co-founder & Chief Scientific Officer

Renowned academic (Titu Maiorescu Faculty of Medicine), expert in immunopathology and clinical validation.

THE ASK

Goals & Funding Round

6–12 MONTH GOALS

- Establish the new BioTech spin-off
- Complete the in silico screening
- File the international patent application (PCT)

FUNDING ROUND REQUESTED

Pre-Seed / Seed

+ research grants

Use of funds:

Microfluidic equipment and rigorous in vitro / in vivo testing.